Zurich family offices · Cross-border positioning

Zurich family offices. US-facing positioning the American intermediary judges.

GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, SEO/AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.

Holding-holding brand versus operating brand for Zurich single and multi-family offices with US co-investment vehicles, portfolio-company US rollouts, or direct US platform-building. Swiss discretion carries standing in Paradeplatz. It does not travel to the American private banker, US family-office peer, or general partner judging the same materials in New York.

Why Zurich family offices arrive here.

The family office has built standing in Zurich through the Paradeplatz-tier private-banking ecosystem, cantonal-grade governance, and quiet compounding across a generation of capital. The name carries among Swiss peers. Governance is clean. The portfolio performs. Then a US co-investment vehicle forms, a portfolio company rolls out in the United States, a US family-office peer requests a meeting, or an American general partner asks for materials. The gap pages and sales materials in the first exchange.

US intermediaries, American private bankers, US family-office peers, and general partners, evaluate Swiss discretion as category absence rather than depth. Holding-brand collateral built for a Zurich audience that already knows the name arrives on the desk of a New York buyer who does not. The absence of a US category anchor, a US outcome claim, and a US peer set leaves the frame empty. The American fills the empty frame with Swiss stereotypes or with nothing at all, and the conversation loses momentum before the governance and thesis can carry weight.

The instinct is to produce more polished Paradeplatz-tier collateral or to fold the portfolio company further into the family narrative for credibility. Both instincts deepen the problem. What the US intermediary needs is two clear public layers that do different jobs, with the seam between them visible, and an operating brand that leads with a US category claim before Swiss origin sits as one supporting fact rather than the dominant one.

The US private banker is not evaluating the family. They are trying to locate the company. Swiss discretion and the holding-brand overflow have made that harder than it should be. House view on Zurich family-office positioning

Portfolio shapes inside Zurich family offices.

  • Family-office-backed medtech. Zurich family-office holdings inside the Swiss medtech cluster entering US procurement, reimbursement, KOL, and commercial channels where Swiss regulatory posture does not substitute for US commercial credibility and the holding-brand frame does not provide the category anchor the American buyer needs.
  • Biotech. Zurich and Basel-adjacent biotech holdings carrying pipeline assets, IP, and co-development positions strong enough for US commercialisation whose US-facing materials do not yet land with US investors, KOLs, or payers. Academic-rigour staff bios and specification-heavy collateral fill the positions US buyers expect outcome claims to occupy.
  • Industrials. Swiss industrial groups and engineering-led Mittelstand-adjacent operators held inside family-office structures, entering US markets through acquisition, subsidiary, or direct outbound, where process rigour does not translate as commercial depth to US procurement.
  • Engineering-commercial holdings. Engineer-led portfolio companies whose product works and whose Swiss-facing story holds, and whose US materials land as technical specification rather than commercial positioning on the pages and sales materials the American buyer evaluates.
  • Portfolio-company US commercialisation. Zurich family-office portfolio companies at the point of launching or scaling in the United States, where the operating brand has to stand on a US category claim and a US peer set without the holding brand crowding the frame.

What Swiss discretion and holding-brand overflow cost in America.

  • Holding brand and operating brand land as one undifferentiated entity. The US intermediary cannot tell where the Zurich family office ends and the portfolio company begins, and judges the operating brand through the family frame rather than on its own commercial claim.
  • Paradeplatz prestige does not translate to US intermediary due-diligence. Bahnhofstrasse adjacency, Zurich tower addresses, and cantonal-tier references are not signals the American private banker or US family-office peer can verify or place.
  • CHF-indexed case studies and Swiss-denominated track records. The US co-investor has to convert and re-contextualise before the result can register, and most will not finish the translation.
  • Academic-rigour staff bios built on Swiss university chairs, ETH or University-of-Zurich credentials, and long-form professional standing. The American buyer is scanning for a US peer set, US operating history, and US outcome references, and the frame does not provide them.
  • Governance language built for the Zurich register lands as opaque in the American buyer language. Phrasing that signals institutional seriousness in Paradeplatz lands as evasion to a US intermediary, and the buyer pulls back rather than push for clarification.
  • Absence of US-peer-set references on the operating brand. The portfolio company never names the American firms it competes with, co-invests alongside, or sells into, and the US allocator cannot place it on a comparison axis.
  • Swiss understatement filling hero positions where US buyers expect category and outcome claims. The homepage headline, the first line of the deck, and the opening paragraph of the portfolio-company one-pager default to process, restraint, and legacy, and the US buyer encounters them before a category has been named.

The family office is not the problem. The portfolio is not the problem. The two pages and sales materials are doing each other's job, and Swiss discretion is filling the frame the US category claim should have occupied.

How engagements start

Entry routes for Zurich family offices.

Market-Entry Marketing Sprint

Six to ten weeks. Single US category or single portfolio company. GMA rebuilds positioning, price presentation, messaging, and proof and trust system for the American co-investor, private banker, or US buyer, then launches it into market.

See the Sprint →

Cross-Border Marketing Build

Three to six months. Holding-brand and operating-brand touchpoints rebuilt together, with the seam between them defined and visible. Typical when a US co-investment closes or a Zurich-held portfolio-company US rollout is imminent.

See the Build →

Global Marketing Partnership

Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across the holding brand and several portfolio-company pages and sales materials. Standard shape for Zurich family offices with multiple US-facing brands or co-investment positions in play.

See the Partnership →

See all engagements →

What this work does not include.

No legal services. No Swiss company formation or US entity formation. No SFO or MFO structure design. No foundation, trust, or SPV setup. No FINMA licensing, EB-5, E-2, L-1, or O-1 visa work. No US tax structuring, FATCA analysis, CRS analysis, or double-tax-treaty analysis. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting.

These belong with Swiss counsel who specialise in family-office structuring and US entry, and with US counsel on the American side. GMA works inside the parameters they set. When a marketing decision carries legal, tax, or fiduciary implications, GMA flags it and defers before execution.

Frequently asked.

The two brands do different jobs. The holding brand carries family standing, governance, and the long-arc capital thesis Zurich buyers already know. The operating brand carries a US category, a US outcome claim, and a US peer set. When the two collapse into one surface, the US intermediary judges the portfolio company through the family-office prestige and Swiss origin together, and cannot locate the commercial category. The work is to build two distinct public layers, each passing the filter its audience uses, with the seam between them defined and visible.

Family-office-backed medtech, biotech, industrials, engineering-commercial holdings, and portfolio-company US commercialisation. The pattern is consistent across these sectors: the US category anchor is missing, the US peer set is absent, the holding brand bleeds into the operating brand, and Swiss understatement fills hero positions where US buyers expect outcome claims. Fit is checked against the concrete US move, not published sector lists.

Yes. A common arrival route is a Zurich lawyer, tax specialist, trust officer, or multi-family office introducing a client company whose holding structure is about to deploy capital into US co-investment or US platform-building. The fiduciary retains the client relationship. GMA designs the US website, proof, offer, and follow-up inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.

Yes. The Zurich corridor covers Basel-adjacent biotech and medtech owners whose pipeline assets and IP are strong enough for US commercialisation but whose US-facing positioning does not yet land with US investors, KOLs, or payers. The work addresses the same buyer-language problem: academic-rigour bios, CHF-indexed track records, and Swiss understatement filling the hero where a US category claim and a US peer set belong.

With an inquiry through the contact form and an inquiry screening. GMA runs three engagements: Market-Entry Marketing Sprint (6 to 10 weeks), Cross-Border Marketing Build (3 to 6 months), or Global Marketing Partnership (monthly retainer, 12-month minimum). GMA confirms fit and pricing after the inquiry screening. Public prices are not listed. Family-office engagements most often begin as a Build or Partnership because the holding brand and several portfolio websites, decks, and sales materials are typically in scope at once.

Further on Zurich and the US corridor.

Cities

Zurich corridor gate.

The wider Zurich marketing starting point for family offices, fiduciaries, and medtech, biotech, and engineering-commercial owners moving into the United States.

See the Zurich gate →
Cities

Zurich fiduciaries.

Zurich lawyers, tax specialists, trust officers, and family-office teams introducing client companies to US market engagements. No referral fee. Confidential introduction. No commission.

See fiduciaries in Zurich →
Knowledge

Zurich medtech and biotech US entry.

Playbook for Zurich medtech and biotech owners carrying pipeline assets and IP into US commercialisation.

Open the piece →

Check why the buyer is not moving.

If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?

Action that should happenThe buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person.
What may be unclearIf that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up.
What to inspectCheck the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors.
Next stepIf the break is commercial, continue to /engagements/ or /contact/#inquiry.

Start the inquiry →

Tell us what the US is doing to your portfolio websites, decks, and sales materials.

Describe the holding brand, the operating brands in play, and where the US intermediary stalls. Response within one business day.

Start the inquiry
Start the inquiry